Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A limited sampling strategy for cyclophosphamide pharmacokinetics.

M J Egorin1, A Forrest, C P Belani

  • 1Division of Developmental Therapeutics, University of Maryland Cancer Center, Baltimore, Maryland 21201.

Cancer Research
|June 1, 1989
PubMed
Summary

A new limited sampling strategy accurately estimates cyclophosphamide

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How to transform urban institutional green spaces into Ancillary Botanic Gardens to expand informal botanical learning opportunities in cities.

Scientific reports·2023
Same author

In pursuit of the triple crown: mechanism-based pharmacodynamic modelling for the optimization of three-drug combinations against KPC-producing Klebsiella pneumoniae.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2020
Same author

Using machine learning to optimize antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter baumannii.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2020
Same author

Assessment and modelling of antibacterial combination regimens.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2017
Same author

Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV-Infected Subjects With Aging Biomarkers.

CPT: pharmacometrics & systems pharmacology·2016
Same author

p16<sup>INK4a</sup> , a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV-Infected Subjects.

CPT: pharmacometrics & systems pharmacology·2016

Area of Science:

  • Pharmacokinetics and Drug Metabolism
  • Clinical Pharmacology
  • Biostatistics

Background:

  • Accurate estimation of the area under the curve (AUC) is crucial for understanding cyclophosphamide pharmacokinetics.
  • Traditional methods for AUC calculation require extensive blood sampling, which can be impractical in clinical settings.

Purpose of the Study:

  • To develop and validate a limited sampling strategy for estimating cyclophosphamide's plasma concentration-time AUC.
  • To simplify pharmacokinetic assessments in clinical trials and patient monitoring.

Main Methods:

  • Developed a predictive model using stepwise regression analysis on pharmacokinetic data from 29 studies.
  • Validated the model prospectively using data from 14 independent studies with varying cyclophosphamide dosages.

Related Experiment Videos

  • The final model uses plasma concentrations at 1, 4, and 24 hours post-infusion to predict AUC.

    • Main Results:

    • The developed sampling strategy demonstrated high predictive accuracy (r=0.98 in training, r=0.94 in validation).
    • The strategy was found to be unbiased (mean error 3.3%) and precise (mean absolute error 9.3%).
    • The formula derived is AUC = 40.18C24 + 8.79C4 + 0.83C1 - 28 (dosage/1000).

    Conclusions:

    • A validated, limited three-point sampling strategy effectively estimates cyclophosphamide AUC.
    • This simplified approach facilitates the correlation of cyclophosphamide pharmacokinetics with therapeutic and toxic effects in ongoing clinical trials.